Management of congenital toxoplasmosis in France: Current data;Prise en charge de la toxoplasmose congénitale en France: Données actuelles

Presse Medicale

Volumn 39, Issue 5, 2010, Pages 530-538

  Garcia Méric, Patricia ^a   Franck, Jacqueline ^b   Dumon, Henri ^b   Piarroux, Renaud ^b  

^a HÔPITAL DE LA CONCEPTION   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ELVORINE; FANSIDAR; FOLIC ACID; FOLINATE CALCIUM; FOLINORAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; OSFOLATE; PROTOZOON ANTIBODY; PYRIMETHAMINE; SPIRAMYCIN; SULFADIAZINE; UNCLASSIFIED DRUG;

AMNION FLUID; BIOSURVEILLANCE; CHOROIDITIS; CONGENITAL TOXOPLASMOSIS; DENMARK; DISEASE SEVERITY; DRUG EFFICACY; ECHOGRAPHY; EUROPE; FETUS; FETUS DISEASE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; FRANCE; GESTATIONAL AGE; HEALTH CARE POLICY; HUMAN; HYGIENE; INFECTION PREVENTION; INFECTION RISK; INOCULATION; MATERNAL NUTRITION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; PLACENTA; PLACENTAL TRANSFER; POLYMERASE CHAIN REACTION; POSTNATAL CARE; PRENATAL DIAGNOSIS; SCREENING TEST; SEROLOGY; SHORT SURVEY; THIRD TRIMESTER PREGNANCY; TOXOPLASMA GONDII; VERTICAL TRANSMISSION;

ANTIPROTOZOAL AGENTS; COCCIDIOSTATS; FEMALE; FRANCE; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MASS SCREENING; POPULATION SURVEILLANCE; PREGNANCY; PRENATAL DIAGNOSIS; PYRIMETHAMINE; SPIRAMYCIN; SULFONAMIDES; TOXOPLASMOSIS, CONGENITAL;

EID: 77952745616     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2009.09.016     Document Type: Short Survey

References (64)

1. Dubey J.P. Advance in the life cycle of Toxoplasma gondii. Int J Parasitol 1998, 28:1019-1024.
2. Bessières M.H., Cassaing S., Fillaux J., Berrebi A. Toxoplasmose et grossesse. Revue Francophone des Laboratoires 2008, 402:39-50.
3. Berger F., Goulet V., Le Strat Yann, Desenclos J.C. Toxoplasmose chez les femmes enceintes en France: évolution de la séroprévalence et de l'incidence et facteurs associés, 1995-2003. Bull Epidemiol Hebd 2008, 14-15:117-121.
4. Robert-Gangneux F., Yera H., D'Herve D., Guiguen C. Congenital toxoplasmosis after a preconceptional or periconceptional maternal infection. Ped Infect Dis J 2009, 28:660-661.
5. Chemla C., Villena I., Aubert D., Hornoy P., Dupouy D., Leroux B., et al. Preconception seroconversion and maternal seronegativity at delivery do not rule out the risk of congenital toxoplasmosis. Clin Diagn Lab Immunol 2002, 9:489-490.
6. Marty P., Bongain A., Rahal A., Thulliez P., Wasfi D., Lambert J.C., et al. Prenatal diagnosis of severe fetal toxoplasmosis as a result of toxoplasmic reactivation in an HIV-1 seropositive woman. Prenat Diagn 1994, 14:414-415.
7. D'Ercole C., Boubli L., Franck J., Casta M., Harle J.R., Chagnon C., et al. Recurrent congenital toxoplasmosis in a woman with lupus erythematosus. Prenat Diagn 1995, 15:1171-1175.
8. Kodjikian L., Hoigne I., Adam O., Jacquier P., Aebi-Ochsner C., Aebi C., et al. Vertical transmission of toxoplasmosis from a chronically infected immunocompetent woman. Pediatr Infect Dis J 2004, 23:272-274.
9. Silveira C., Ferreira R., Muccioli C., Nussenblatt R., Belfort R. Toxoplasmosis transmitted to a newborn from the mother infected 20 years earlier. Am J Ophtalmol 2003, 136:370-371.
10. Elbez-Rubinstein A., Ajzenberg D., Dardé M.L., Cohen R., Dumètre A., Yera H., et al. Congenital toxoplasmosis and reinfection during pregnancy: case report, strain characterization, experimental model of reinfection and review. J Infect Dis 2009, 199:280-285.
11. Leroy V, Raeber PA, Petersen E, Salmi LR, Kaminski M, Villena I et al. National public health policies and routine programs to prevent congenital toxoplasmosis. European TOXO prevention project 2005. http://eurotoxo.isped.u-bordeaux2.fr/WWW_PUBLIC/DOC/EUROTOXO_R1_P3_European_national_policies_Dec2005.pdf.
12. Petersen E. Toxoplasmosis. Semin Fetal Neonatal Med 2007, 12:214-223.
13. Jones J.L., Kruszon-Moran D., Sanders-Lewis K., Wilson M. Toxoplasma gondii infection in the United States, 1999-2004, decline from the prior decade. Am J Trop Med Hyg 2007, 77:405-410.
14. Kodjikian L., Wallon M., Fleury J., Denis P., Binquet C., Peyron F., et al. Ocular manifestations in congenital toxoplasmosis. Graefe's Arch Clin Exp Ophtalmol 2006, 244:14-21.
15. Tan H.K., Schmidt D., Stanford M., Teär-Fahnehjelm K., Ferret N., Salt A., et al. Risk of visual impairment in children with congenital toxoplasmic retinochoroiditis. Am J Ophtalmol 2007, 144:648-653.
16. The SYROCOT (Systematic review on congenital toxoplasmosis) study group. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta- analysis of individual patient's data. Lancet 2007; 369:115-22.
17. Phan L., Kasza K., Jalbrzilowski J., Noble G., Latkany P., Kuo A., et al. Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophtalmology 2008, 115:553-559.
18. Freeman K., Tan H.K., Prusa A., Petersen E., Buffolano W., Malm G., et al. Predictors of retinochoroiditis in children with congenital toxoplamosis: European prospective cohort study. Pediatrics 2008, 121:1215-1222.
19. Phan L., Kasza K., Jalbrzilowski J., Noble G., Latkany P., Kuo A., et al. Longitudinal study of new eye lesions in children who were not treated during the first year of life. Am J Ophtalmol 2008, 146:375-384.
20. Pinard J.A., Leslie N.S., Irvine P.J. Maternal serologic screening for toxoplasmosis. J Midwifery Womens Health 2003, 48:308-316.
21. Thulliez P., Romand S. Infections virales et toxoplasmose materno-foetales 2001, Elsevier, Paris.
22. Berrebi A., Kobuch W.E., Bessieres M.H., Bloom M.C., Rolland M., Sarramon M.F., et al. Termination of pregnancy for maternal toxoplasmosis. Lancet 1994, 344:36-39.
23. Thalib L., Gras L., Romand S., Prusa A., Bessieres M.H., Petersen E., et al. Prediction of congenital toxoplasmosis by polymerase chain reaction analysis of amniotic fluid. Br J Obstet Gynecol 2005, 112:567-574.
24. Maubon D., Brenier-Pinchart M.P., Fricker-Hidalgo H., Pelloux H. Apport de la PCR quantitative dans le diagnostic de la toxoplasmose: la voie de la standardisation?. Pathologie Biologie 2007, 55:304-311.
25. Romand S., Chosson M., Franck J., Wallon M., Kieffer F., Kaiser K., et al. Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with Toxoplasma gondii. Am J Obstet Gynecol 2004, 190:797-802.
26. Kasper D.C., Sadeghi K., Prusa A.-R., Reischer G.H., Kratochwill K., Förster-Waldl E., et al. Quantitative real-time polymerase chain reaction for the accurate detection of Toxoplasma gondii in amniotic fluid. Diagn Microbiol Infect Dis 2009, 63:10-15.
27. Bessières M.H., Berrebi A., Cassaing S., Fillaux J., Cambus J.P., Berry A., et al. Diagnosis of congenital toxoplasmosis: prenatal and neonatal evaluation of methods used in Toulouse University Hospital and incidence of congenital toxoplasmosis. Mem Inst Oswaldo Cruz 2009, 104:389-392.
28. Rorman E., Stein Zamir C., Rilkis I., Ben-David H. Congenital toxoplasmosis - prenatal aspects of Toxoplasma gondii infection. Reprod Toxicol 2006, 21:458-472.
29. Jacquemard F. Signes échographiques de la toxoplasmose congénitale. Arch Pédiatr 2003, 10:35-38.
30. Kieffer F., Wallon M., Garcia P., Thulliez P., Peyron F., Franck J. Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J 2008, 27:27-32.
31. Berrebi A., Bardou M., Bessières M.H., Nowakowka D., Castagno R., Rolland M., et al. Outcome for children infected with congenital toxoplasmosis in the first trimester and with normal ultrasound: A study of 36 cases. Eur J Obstet Gynecol Reprod Biol 2007, 135:53-57.
32. Roizen N., Kasza K., Karrison T., Mets M., Noble A.G., Boyer K., et al. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics 2006, 118:379-390.
33. Kodjikian L., Wallon M., Fleury J., Denis P., Binquet C., Peyron F., et al. Ocular manifestations in congenital toxoplasmosis. Graefes Arch Clin Exp Ophtalmol 2006, 244:14-21.
34. Melamed J., Eckert G.U., Spadoni V.S., Lago E.G., Uberti F. Ocular manifestations of congenital toxoplasmosis. Eye 2009, 10.1038/eye.2009.
35. Bessières M.H., Berrebi A., Rolland M., Bloom M.C., Roques C., Cassaing S., et al. Neonatal screening for congenital toxoplasmosis in a cohort of 165 women infected during pregnancy and influence of in utero treatment on the results of neonatal tests. Eur J Obstet Gynecol Reprod Biol 2001, 94:37-45.
36. Pinon J.M., Dumon H., Chemla C., Franck J., Petersen E., Lebech M., et al. Strategy for diagnosis of congenital toxoplasmosis: evaluation of methods comparing mothers and newborns and standard methods for post-natal detection of immunoglobulin G, M and A antibodies. J Clin Microbiol 2001, 39:2267-2271.
37. Villena I., Aubert D., Leroux B., Dupouy D., Talmud M., Chemla C., et al. Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Scand J Infect Dis 1998, 30:295-300.
38. Afssa. Rapport du groupe de travail « Toxoplasm gondii ». Toxoplasmose: Etat des connaissances et évaluation du risque lié à l'alimentation. 2005. http://fulltext.bdsp.ehesp.fr.
39. Chemla C., Villena I., Trenque T., Pinon J.M. Effets secondaires du traitement anténatal de la toxoplasmose congénitale. Presse Med 2005, 34:1719.
40. Boyer K.M., Holfels E., Roizen N., Swisher C., Mack D., Remington J., et al. Toxoplasmosis Study Group. Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. Am J Obstet Gynecol 2005, 192:564-571.
41. Foulon W., Villena I., Stray-Pedersen B., Decoster A., Lappalainen M., Pinon J.M., et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 1999, 180:410-415.
42. Gilbert R.E., Gras L., Wallon M., Peyron F., Ades A.E., Dunn D.T. Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: retrospective cohort study of 554 mother-child pairs in Lyon, France. Int J Epidemiol 2001, 30:1303-1308.
43. Gras L., Wallon M., Pollak A., Cortina-Borja M., Evengard B., Hayde M., et al. European Multicenter Study on Congenital Toxoplasmosis. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr 2005, 94:1721-1731.
44. Petersen E., Schmidt D.R. Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options?. Expert Rev Anti Infect Ther 2003, 1:175-182.
45. Kami K. Time to screen for congenital toxoplasmosis?. Clin Infect Dis 2006, 42:1395-1397.
46. Gras L., Gilbert R.E., Ades A.E., Dunn D.T. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol 2001, 30:1309-1313.
47. Kieffer F., Thulliez P., Brézin A., Nobre R., Romand S., Yi-Gallimard E., et al. Traitement de la toxoplasmose congénitale non sévère par sulfadiazine et pyriméthamine en continu pendant un an: à propos de 46 cas. Arch Pédiatr 2002, 9:7-13.
48. Johannessen J.K., Christiansen I., Schmidt D.R., Petersen E., Hansen S.H. Simultaneous determination of pyrimethamine, sulfadiazine and N-acetyl-sulfadiazine in plasma for monitoring infants in treatment of congenital toxoplasmosis. J Pharm Biomed Anal 2005, 36:1093-1098.
49. Corvaisier S., Charpiat B., Mounier C., Wallon M., Leboucher G., Al Kurdi M., et al. Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. Antimicrob Agents Chemother 2004, 48:3794-3800.
50. Trenque T., Simon N., Villena I., Chemla C., Quereux C., Leroux B., et al. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Br J Clin Pharmacol 2004, 57:735-741.
51. Jaisson-Hot I., Wallon M., al Kurdi M., Thulliez P., Kahi S., Cozon G., et al. Congenital toxoplasmosis. Transitory negative serology. Presse Med 2001, 30:1001-1004.
52. Fortier B., Coignard-Chatain C., Dao A., Rouland V., Valat A.S., Vinatier D., et al. Etude des poussées cliniques évolutives et des rebonds sérologiques d'enfants atteints de toxoplasmose congénitale et suivis durant les 2 premières années de vie. Arch Pédiatr 1997, 4:940-946.
53. Wallon M., Cozon G., Ecochard R., Lewin P., Peyron F. Serological rebound in congenital toxoplasmosis: long-term follow-up of 133 children. Eur J Pediatr 2001, 160:534-540.
54. Wilson C.B., Remington J.S., Stagno S., Reynolds D.W. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980, 66:767-774.
55. Koppe J.G., Loewer-Sieger D.H., de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 1986, 1:254-256.
56. Couvreur J., Desmonts G., Aron-Rosa D. Ocular prognosis in congenital toxoplasmosis: the role of treatment. Preliminary communication. Ann Pediatr 1984, 31:855-858.
57. Wallon M., Kodjikian L., Binquet C., Garweg J., Fleury J., Quantin C., et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004, 113:1567-1572.
58. Schmidt D.R., Hogh B., Andersen O., Fuchs J., Fledelius H., Petersen E. The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999-2002. Arch Dis Child 2006, 91:661-665.
59. Holland G.N., Lewis K.G. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol 2002, 134:102-114.
60. Silveira C., Belfort R., Muccioli C., Holland G.N., Victora C.G., Horta B.L., et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol 2002, 134:41-46.
61. Derouin F. Anti-toxoplasmosis drugs. Curr Opin Investig Drugs 2001, 2:1368-1374.
62. King L., Villena I., Ancelle T., Wallon M., Garcia P., Thulliez P., et al. La toxoplasmose congénitale: mise en place d'un dispositif de surveillance en France. BEH thématique 2008, 14-15:122-124.
63. McLeod R., Boyer K., Karrison T., Kasza K., Swisher C., Roizen N., et al. toxoplasmosis study group. outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis 2006, 42:1383-1394.
64. Chêne G., Thiébaut R. Options for clinical trials of pre and post-natal treatments for congenital toxoplasmosis. Mem Inst Oswaldo Cruz 2009, 104:299-304.